| 25.9168 0.137 (0.53%) | 01-26 13:01 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 35.01 | 1-year : | 40.89 |
| Resists | First : | 29.97 | Second : | 35.01 |
| Pivot price | 23.77  |
|||
| Supports | First : | 20.58 | Second : | 14.78 |
| MAs | MA(5) : | 26.57  |
MA(20) : | 21.77 |
| MA(100) : | 20.39 |
MA(250) : | 20.16 |
|
| MACD | MACD : | 2.2 |
Signal : | 1.7 |
| %K %D | K(14,3) : | 75.2 |
D(3) : | 78.1 |
| RSI | RSI(14): 64.8 |
|||
| 52-week | High : | 29.97 | Low : | 13.3 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ELVN ] has closed below upper band by 38.2%. Bollinger Bands are 206.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 11 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 27.09 - 27.24 | 27.24 - 27.36 |
| Low: | 25.09 - 25.27 | 25.27 - 25.42 |
| Close: | 25.51 - 25.78 | 25.78 - 26.01 |
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.
Fri, 23 Jan 2026
Enliven Therapeutics (ELVN) Stock Analysis: A 53% Upside Potential with Strong Analyst Support - DirectorsTalk Interviews
Thu, 22 Jan 2026
Joseph Lyssikatos Sells 20,000 Shares of Enliven Therapeutics (NASDAQ:ELVN) Stock - MarketBeat
Thu, 22 Jan 2026
Enliven Therapeutics (NASDAQ:ELVN) Director Sells 1,230 Shares - MarketBeat
Mon, 19 Jan 2026
Assessing Enliven Therapeutics (ELVN) Valuation After Positive Phase 1b ENABLE Trial Update - simplywall.st
Mon, 19 Jan 2026
Assessing Enliven Therapeutics (ELVN) Valuation After Positive Phase 1b ENABLE Trial Update - Sahm
Tue, 13 Jan 2026
Enliven Therapeutics: Springing Into 2026 With Data, But I'm Still Cautious (NASDAQ:ELVN) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 59 (M) |
| Shares Float | 38 (M) |
| Held by Insiders | 8.2 (%) |
| Held by Institutions | 103.1 (%) |
| Shares Short | 8,310 (K) |
| Shares Short P.Month | 8,000 (K) |
| EPS | -1.81 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 8.02 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -17.7 % |
| Return on Equity (ttm) | -25.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.89 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -72 (M) |
| Levered Free Cash Flow | -46 (M) |
| PE Ratio | -14.28 |
| PEG Ratio | 0 |
| Price to Book value | 3.21 |
| Price to Sales | 0 |
| Price to Cash Flow | -21.4 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|